Pular para o conteúdo principal
Ranking Invest

CGEN - Compugen Ltd.

Segmento: HealthcareCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Análise Ranking Invest

Valor de Mercado
$ 190.40 Mi
IVR
-0.14Índice proprietário de comparação relativa: -0,14.
IVR2
-0.45Leitura proprietária complementar: -45%.
MLL
-0.45Leitura proprietária complementar: -45%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 57.11 Mi

Dívida Líquida

-$ 11.80 Mi

L4T

-$ 14.14 Mi

MM4T

-188.62%

Indicadores Básicos

ROE

-24.77%

Índices de Previsibilidade

Receita Líquida

G4.76

Lucro

C0.37

Margem

E1.21

Índices de Tendência

Receita Líquida

C5.03

Lucro

B5.56

Margem

F-7.05

Índices de Endividamento

DIV/PAT

-0.21

DIV/L4T

0.83

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.